Article
AJMC in the Press, October 14, 2016
Author(s):
Coverage of our peer-reviewed research in the healthcare and mainstream press.
In the October 3, 2016, edition of Medical Economics, Mark L. Fuerst discussed the commentary in a special issue of The American Journal of Managed Care on novel direct-acting antivirals (DAAs). Darius Lakdawalla, PhD, of the University of Southern California’s Schaeffer Center for Health Policy and Economics, wrote that cost-sharing plans that impose large out-of-pocket costs on DAAs for patients with hepatitis C virus (HCV) are “suboptimal solutions,” because they impose financial burdens on patients “at a time when they are least able to cope with them.” For the rest of the special issue on policy questions surrounding HCV treatment and cost-sharing, click here.
